Trinity Biotech receives MVPHS requirement notice from Nasdaq

Trinity Biotech announced that on November 21 the Company received notice from the Nasdaq Stock Market that the Company is not in compliance with the minimum market value of publicly held shares MVPHS requirement set forth in the Nasdaq Listing Rules. For continued listing on the Nasdaq Global Select Market, registrants are required to maintain a minimum MVPHS of US$15M in accordance with Nasdaq Listing Rule 5450(b)(3)(c). Nasdaq Listing Rule 5810(c)(3)(D) provides that the failure to meet the minimum MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company intends to monitor its MVPHS between now and May 20, and intends to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company will continue to be listed and trade on the Nasdaq Global Market. The Company’s management is evaluating various options available to regain compliance and maintain its continued listing. The Company’s business operations are not affected by the Notification Letter.